MedTrace Logo

Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF

NCT02118831 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2016-05-19

Study results available
· View outcomes & findings →

Summary

Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on circulating vascular endothelial growth factor. In the present prospective study, the investigators evaluated serum drug levels and plasma free vascular endothelial growth factor (VEGF) levels in patients with neovascular age-related macular degeneration following intravitreal injections of ranibizumab, bevacizumab and aflibercept.

Conditions

Interventions

BIOLOGICAL

Blood Sample Collection

Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.

DRUG

Aflibercept

an intravitreal injection of Aflibercept administered three times on a monthly basis.

DRUG

Bevacizumab

an intravitreal injection of Bevacizumab administered three times on a monthly basis.

DRUG

Ranibizumab

an intravitreal injection of Ranibizumab administered three times on a monthly basis.

Sponsors & Collaborators

  • California Retina Consultants

    lead OTHER

Principal Investigators

  • Robert L Avery, MD · California Retina Consultants

  • Melvin D Rabena, BS · California Retina Consultants

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-02-28
Completion
2014-04-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02118831 on ClinicalTrials.gov